Docetaxel-oxaliplatin-capecitabine/5-fluorouracil (DOX/F) followed by docetaxel versus oxaliplatin-capecitabine/5-fluorouracil (CAPOX/FOLFOX) in HER2-negative advanced gastric cancers.

JNCI Cancer Spectr · 2024 · PMC11316615 · PMID 39067037

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significanceP = .07so close (0.05 < p ≤ 0.1)

A greater proportion of patients in Arm A received second-line therapy compared with patients in Arm B (60 [38.7%] vs 40 [26.7%]), but this difference did not reach statistical significance ( P = .07).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.